Druggable targets of the endocannabinoid system: Implications for the treatment of HIV-associated neurocognitive disorder

Mariah M. Wu, Xinwen Zhang, Melissa J. Asher, Stanley A. Thayer

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

HIV-associated neurocognitive disorder (HAND) affects nearly half of all HIV-infected individuals. Synaptodendritic damage correlates with neurocognitive decline in HAND, and many studies have demonstrated that HIV-induced neuronal injury results from excitotoxic and inflammatory mechanisms. The endocannabinoid (eCB) system provides on-demand protection against excitotoxicity and neuroinflammation. Here, we discuss evidence of the neuroprotective and anti-inflammatory properties of the eCB system from in vitro and in vivo studies. We examine the pharmacology of the eCB system and evaluate the therapeutic potential of drugs that modulate eCB signaling to treat HAND. Finally, we provide perspective on the need for additional studies to clarify the role of the eCB system in HIV neurotoxicity and speculate that strategies that enhance eCB signaling might slow cognitive decline in HAND.

Original languageEnglish (US)
Article number146467
JournalBrain Research
Volume1724
DOIs
StatePublished - Dec 1 2019

Bibliographical note

Funding Information:
This work was supported by National Institutes of Health Grants DA007304 and DA044809 to ST. MW was supported by NIH training grant T32 DA007097.

Keywords

  • 2-Arachidonoylglycerol
  • Anandamide
  • Cannabinoid receptor
  • Fatty acid amide hydrolase
  • HIV-1
  • Monoacylglycerol lipase

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Review

Fingerprint Dive into the research topics of 'Druggable targets of the endocannabinoid system: Implications for the treatment of HIV-associated neurocognitive disorder'. Together they form a unique fingerprint.

Cite this